China SXT Pharmaceuticals, Inc. (SXTC): Total Liabilities
$5.05M
As of 2026-03-31
-30.2%
3-year compound annual growth
-23.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $5.05M | -18.9% | 2026-07-01, Balance as of period end |
| 2025-03-31 | $6.22M | -32.3% | 2026-07-01, Balance as of period end |
| 2024-03-31 | $9.20M | -38.1% | 2025-07-31, Balance as of period end |
| 2023-03-31 | $14.86M | -13.2% | 2024-08-13, Balance as of period end |
| 2022-03-31 | $17.12M | -7.9% | 2023-07-31, Balance as of period end |
| 2021-03-31 | $18.59M | +51.1% | 2023-05-19, Balance as of period end |
| 2020-03-31 | $12.30M | +93.3% | 2021-08-13, Balance as of period end |
| 2019-03-31 | $6.36M | +45.5% | 2020-07-31, Balance as of period end |
| 2018-03-31 | $4.37M | n/a | 2019-08-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $5.05M | -18.9% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | $2.45M | +17.9% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $4.11M | -57.1% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.59M | +24.9% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $29.63M | +5.4% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $13.04M | -6.5% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $2.42M | -6.4% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $1.99M | +10.1% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $8.64M | -24.4% |
Compare SXTC, BSPK, NEUP, LGVN side by side · Screen every company in Pharmaceutical Preparations ↗